January 2012

Patheon promotes Mancuso

Tuesday, January 31, 2012

Patheon, a global provider of drug development and manufacturing services, has promoted Antonella Mancuso to president, global commercial operations and chief manufacturing officer, responsible for Patheon’s global commercial  manufacturing operations. Mancuso will assume responsibility for all of Patheon’s commercial operating units in North America and Europe. 

[Read More]

Tyson named chair of Executive Leadership Council

Tuesday, January 31, 2012

Bernard Tyson, president and COO of Kaiser Permanente, has been named chair of the Executive Leadership Council (ELC)—a preeminent organization composed of African-American senior executives from the nation’s Fortune 500 corporations that recognizes the strengths, success, contributions and impact of African-American business leaders. His term runs through Dec. 31, 2013.

[Read More]

FDA approves Erivedge to treat skin cancer

Monday, January 30, 2012

Genentech’s Erivedge (vismodegib) has been approved by the FDA to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body (metastatic).

[Read More]

VGX-100 identified as potential therapy for improving corneal graft survival

Monday, January 30, 2012

Circadian Technologies has published data in Investigative Ophthalmology & Visual Science (IOVS) showing that VEGF-C expression is markedly up-regulated in corneal graft rejection. The data also showed that VEGF-C blockade, through administration of Circadian’s lead development candidate VGX-100, a human antibody against VEGF-C, significantly improved corneal graft survival in an animal model. The data indicates a new therapeutic opportunity for VGX-100 to improve corneal graft survival.

[Read More]